KSE
Search
- Page Path
- HOME > Search
Systematic Review
- Probiotics for preventing neonatal sepsis in preterm neonates: a systematic review and meta-analysis for clinical practice
- Rizka Maulida, Radhian Amandito, Rinawati Rohsiswatmo, Amarila Malik
- Epidemiol Health. 2025;47:e2025051. Published online September 3, 2025
- DOI: https://doi.org/10.4178/epih.e2025051
- 2,959 View
- 114 Download
-
Abstract
Summary
PDF
Supplementary Material -
AbstractLate-onset sepsis (LOS), occurring after 72 hours of birth, is a significant cause of morbidity and mortality especially in preterm neonates. Probiotics have been proposed as a preventive strategy to enhance gut health, modulate immune responses, and reduce the incidence of neonatal sepsis. We aimed to evaluate the effectiveness of probiotics in preventing neonatal sepsis in preterm neonates, with particular attention to the impact of different strains and dosage regimens. Eligible studies included preterm neonates (≤36 weeks gestational age) with culture-proven LOS and focused on probiotic supplementation. Comprehensive searches were conducted in MEDLINE via PubMed, Cochrane CENTRAL, Scopus, and ProQuest up to July 28, 2024. The Revised Cochrane Risk of Bias Tool (RoB 2.0) was applied to assess study quality, and a random-effects meta-analysis was performed using Review Manager version 5.4. Additionally, the certainty of the body of evidence was evaluated using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one studies including 8,040 preterm neonates were reviewed. Meta-analysis demonstrated that probiotics significantly reduced the incidence of LOS (pooled risk ratio [RR], 0.83; 95% confidence interval [CI], 0.72 to 0.95). Greater efficacy was observed with multistrain formulations (RR, 0.76; 95% CI, 0.72 to 0.95) and low-dose regimens (RR, 0.72; 95% CI, 0.56 to 0.91). Probiotic supplementation was also associated with shorter hospital stays and a trend toward lower mortality, although the latter did not reach statistical significance. To effectively reduce LOS in preterm neonates, specific combinations of multistrain probiotics and optimized dosing strategies may provide the most benefit.
-
SummaryKey Message
• Late-onset sepsis (LOS) is a major cause of morbidity and mortality in preterm neonates, and the optimal approach for using probiotics to prevent LOS remains uncertain. • Probiotics significantly reduce LOS risk (RR, 0.83; 95% CI, 0.72 to 0.95), with multistrain (RR, 0.76; 95% CI, 0.72 to 0.95) and low-dose formulations (RR, 0.72; 95% CI, 0.56 to 0.91) showing greater efficacy. Supplementation shortens hospital stays. • These findings support the use in probiotics in neonatal care, as they enhance immune defense and reduce infection burden. • This study informs clinical guidelines and highlights probiotics’ potential to improve neonatal outcomes and reduce healthcare costs.
First
Prev
